• Search
  • Advanced Search
Review Article
The Korean Journal of Urological Oncology 2012;10(1):1-5.
Published online April 30, 2012.
고위험군 전립선암이란 무엇인가?
박승철
원광대학교 의과대학 비뇨기과학교실, 원광의과학연구소
What is the High Risk Prostate Cancer?
Seung Chol Park
Department of Urology, Wonkwang University School of Medicine and Hospital, Institute of Wonkwang Medical Science, Iksan, Korea
Correspondence:  Seung Chol Park
Abstract
An accurate estimate of overall and disease-specific survival is critical for an informed discussion of treatment options among men with newly diagnosed prostate cancer. The risk of relapse following therapy has been estimated by using multiple definitions ranging from a single parameter, including clinical stage, prostate specific antigen, and Gleason score, to a combination of variables to scoring system or nomogram definition. The most commonly accepted definition was proposed by D'Amico and defines high risk prostate cancer as prostate specific antigen more than 20ng/ml or Gleason score 8-10 or clinical stage of at least T2c. High risk prostate cancer had shown low disease specific survival and overall survival. Long-term survival depends, in part, on risks posed by the tumors and risks posed by existing comorbidity. Therefore more accurate stratification of the individual patient's risk for progression and likelihood of response to treatment are required. And the new biomarkers are needed to predict survival. This article reviewed the definition of high risk prostate cancer and natural history of high risk prostate cancer. (Korean J Urol Oncol 2012;10:1-5)
Key Words: Prostate cancer, Prognosis
TOOLS
METRICS Graph View
  • 1,530 View
  • 1,482 Download
Related articles

Treatment of Patients With High Risk Prostate Cancer2019 April;17(1)

The Treatments for Intermediate Risk Prostate Cancer2019 April;17(1)

The Treatments for Low-Risk Prostate Cancer2019 April;17(1)

Choroidal Metastasis from Prostate Cancer2016 December;14(3)

What’s New in Radiation Therapy for High Risk Prostate Cancer2014 December;12(3)

Editorial Office
Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine,
101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
TEL: +82-2-2072-0817,   FAX: +82-2-742-4665   Email: journal@e-juo.org
Korean Urological Oncology Society
50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Tel: +82-2-704-8574, E-mail: kspe.editor@gmail.com

Copyright © The Korean Urological Oncology Society.

Developed in M2PI